TransMedics Group, Inc. (TMDX) Raises 2026 Revenue Guidance to $764M–$774M
TransMedics Group (TMDX) reported Q3 2026 revenue of $203.0M, up 41% YoY. The company raised its 2026 revenue guidance to $764M–$774M, including $14M from PAD Aviation. Despite revenue growth, net income decreased YoY. Next catalysts include meeting the updated revenue range and progress in clinical trials.
How this was made
The 30-second read
Why it matters
The guidance raise reflects confidence in trial progress and new PAD Aviation revenue, likely prompting short‑term buying interest.
Market read
First‑report of FY 2026 guidance lift; material for traders evaluating biotech exposure.
What to watch
Potential regulatory delays or competitive advances in organ‑preservation technology could temper upside.
Background
TransMedics reported Q3 2026 revenue of $203M, a 41% YoY increase, and highlighted upcoming ENHANCE Heart Part B and DENOVO Lung trial milestones.
Ticker impact
TransMedics raised FY 2026 revenue guidance to $764M‑$774M, up from prior outlook, after reporting Q3 revenue of $203M.
upward pressure as investors price in higher revenue expectations
Revenue guidance is a material, forward‑looking metric; the increase of $10M‑$20M range is new information and moves the valuation baseline.
Market effects
Boosts sentiment for the broader organ‑preservation and transplant technology sector.
May lift other US‑listed biotech stocks with similar trial pipelines.
Limited to investors tracking medical‑device and biotech earnings.
Counterpoint
Guidance may be overly optimistic if trial data fails to meet expectations, risking a pull‑back.
Key entities
- companyTransMedics Group, Inc.
US‑listed biotech focused on organ‑preservation technologies.
